Objective: During the past decade, thoracic endovascular aortic repair (TEVAR) has increased as a treatment option for a variety of aortic pathologic processes. Despite this rise in the use of thoracic stent grafts, real-world outcomes from a robust, adjudicated, contemporary data set have yet to be reported. Previous studies have shown periprocedural mortality rates between 1.5% and 9.5% and procedure-related stroke rates of 2.3% to 8.2%. With advances in device engineering and increased experience of physicians, we hypothesized that the rates of these complications would be reduced in a more recent sample set. The purpose of this study was to determine current rates of mortality and stroke after TEVAR, to identify risk factors that contribute to 30-day mortality, and to develop a simple scoring system that allows risk stratification of patients undergoing TEVAR.
Since U.S. Food and Drug Administration approval in 2005, thoracic endovascular aortic repair (TEVAR) has gained popularity as a minimally invasive treatment option for a range of thoracic aortic diseases. Indications for the procedure have expanded from thoracic aortic aneurysm alone to include acute and chronic aortic dissection, penetrating aortic ulcer, ruptured thoracic aortic aneurysm, and traumatic aortic injury. It has rapidly become the procedure of choice for treating patients with thoracic disease processes. [1] [2] [3] [4] Numerous prospective, nonrandomized, and multi-institutional trials have demonstrated reduced or noninferior morbidity and mortality rates compared with open surgical repair. [5] [6] [7] [8] [9] During the past decade, both stent graft devices and techniques have evolved to refine the TEVAR procedure.
Despite the widespread use of this technology, we still lack evidence to support a set of defined patient-and procedure-related variables that may be consistently assessed in efforts to reduce perioperative TEVAR morbidity and mortality. To improve outcomes, it is necessary to focus our attention on the most recently available study period during which procedural implementation has been largely unchanged. The aim of this study was to use the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database from 2013 to 2014 to identify risk factors associated with 30-day mortality after TEVAR for all thoracic aortic disease and to develop a scoring system for evaluating preoperative risk in patients being considered for the procedure.
METHODS
Data acquisition. Patients undergoing TEVAR for all aortic disease were identified from the 2013 to 2014 ACS NSQIP Participant Use Files using Current Procedural Terminology codes 33880 and 33881. Preoperative through 30-day postoperative data are prospectively collected by trained surgical clinical reviewers at each participating hospital to generate a representative sample of eligible cases. The annual Participant Use File User Guide provides standardized definitions for each variable, and the data are abstracted by examining patient medical records, communicating with treating physicians, and directly contacting patients as necessary. 10 The 2013 and 2014 Participant Use Files contained adult patient-level data from 435 and 517 hospitals, respectively. For Health Insurance Portability and Accountability Act compliance, the distribution of cases per participating center is not disclosed. There were no exclusion criteria for this retrospective cohort study. The patient data are deidentified; informed consent was not required, and the study was determined to be exempt from Institutional Review Board approval.
Data collection. Demographic and preoperative variables considered included sex, race (white or not white), transfer status (from home or not from home), emergency case, American Society of Anesthesiologists (ASA) classification (1 or 2, normal healthy or mild systemic disease; or 3, 4, or 5, severe systemic disease that is or is not a constant threat to life or moribund), diabetes mellitus (no or oral medication/insulin dependent), smoking status (within 1 year of operation), dyspnea (none or moderate exertion/at rest), ventilator dependence (ventilator-assisted respiration in the 48 hours before surgery, excluding treatment of sleep apnea with continuous positive airway pressure), chronic obstructive pulmonary disease, congestive heart failure, hypertension requiring medication, dialysis, disseminated cancer, weight loss (>10% in last 6 months), steroid use, bleeding disorder, functional status before surgery (independent or partially/totally dependent), pneumonia, urinary tract infection, transfusion (>4 units in the 72 hours before surgery), preoperative wound infection, systemic sepsis (systemic inflammatory response syndrome or sepsis/septic shock), preoperative white blood cell count (#12 Â 10 9 /L or >12 Â 10 9 /L), preoperative hematocrit, preoperative creatinine concentration (<1.8 mg/dL or $1.8 mg/dL), 11 preoperative albumin concentration, and age (<80 years or $80 years). Age was separated into two groups above and below this particular cutoff age as vascular surgeons are increasingly faced with making treatment decisions for older patients. [12] [13] [14] Intraoperative variables considered included surgical specialty, principal anesthesia technique, left subclavian coverage, thoracic aortic dissection, and wound classification (clean or clean-contaminated, contaminated, or dirty-infected). Postoperative variables considered included superficial surgical site infections, pneumonia, unplanned intubation, pulmonary embolism, ventilator dependence (>48 hours), acute renal failure, progressive renal insufficiency, urinary tract infection, cerebrovascular accident, cardiac arrest requiring cardiopulmonary resuscitation, myocardial infarction, transfusions, deep venous thrombosis requiring therapy, sepsis, septic shock, total hospital length of stay, length of stay >30 days, readmission, and unplanned reoperation. The variable of days from operation to death was used to determine which patients had the primary outcome of 30-day all-cause mortality. The 30-day postoperative stroke rate was evaluated as a secondary outcome.
Statistical analysis. In descriptive analyses, categorical variables are represented as frequency (%); continuous variables are reported as mean 6 standard deviation. Bivariate analyses with the outcome of 30-day all-cause mortality were conducted for preoperative, intra- Recommendation: The authors suggest a scoring system using six preoperative factors to predict mortality after thoracic endovascular aortic repair. Table I , online only). These analyses were repeated with the outcome of 30-day postoperative stroke for preoperative and intraoperative variables only. A multivariable logistic regression model for 30-day mortality was constructed using backward selection with P < .10 as the stay criterion. Preoperative variables with P < .10 in bivariate analysis and <5% missing data were considered in the initial model. Variables included in the model were assessed for potential interaction. Additional variables of clinical significance were selected for model entry. The C statistic, or area under the curve, and the HosmerLemeshow goodness-of-fit test were used to evaluate the model. Variables incorporated in the model were used to generate a risk score. Points were assigned to risk factors significant at P < .05 by rounding their parameter estimates to the closest integer. The risk score was used to calculate predicted probabilities for 30-day mortality that were plotted against observed probabilities to assess calibration of the model. The model underwent internal validation by leave-oneout cross-validation, for which one observation was set aside from the entire study population, and a model was fitted to the remainder of the data. The model was used to predict the outcome for the "missing" observation, and the process was repeated with each observation in the study cohort. Again, the C statistic was used to evaluate the models produced in the validation method. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Between 2013 and 2014, a total of 826 patients (473 men, 353 women) underwent TEVAR and were included in the analysis. The mean age was 68.2 6 12.7 years, and 68.8% of patients identified as white. Of the procedures performed, 188 (22.8%) were considered emergent and 396 (48.0%) were considered elective, and 211 (25.5%) patients were transferred from a facility other than home. Demographics of the patients and preoperative characteristics for the study population are outlined in Table I . In descending order of frequency, the most common indications for which the procedure was performed are as follows: 334 thoracic aortic aneurysms without rupture (40.4%), 153 thoracic aortic dissections (18.5%), 79 thoracoabdominal aortic aneurysms without rupture (9.6%), 50 thoracic aortic aneurysms with rupture (6.1%), 43 thoracoabdominal aortic dissections (5.2%), 25 abdominal aortic aneurysms without rupture (3.0%), 14 aortic dissections of unspecified site (1.7%), 18 thoracoabdominal aortic aneurysms with rupture (2.18%), and 6 abdominal aortic aneurysms with rupture (0.7%). Patients observed to have abdominal aortic indications were presumed to have thoracic indications with concomitant abdominal indications. TEVAR was performed by a vascular surgeon in a total of 787 (95.3%) cases, and 292 (35.4%) procedures involved coverage of the left subclavian artery (Supplementary Table II , online only).
The 30-day all-cause mortality in this population of patients was 7.6% (n ¼ 63), with the mortality rate in the subset of patients undergoing elective cases being 2.3% (n ¼ 9); 313 (37.9%) patients experienced at least one postoperative complication (Table II) . The postoperative stroke rate was 4.5% (n ¼ 37), whereas the rate of postoperative acute renal failure was 2.7% (n ¼ 22). The median total length of hospital stay was 5 days (interquartile range, 3-10 days). Ninety-two patients (11.1%) were readmitted within 30 days, with 69 (8.4%) requiring unplanned reoperation (Table II) .
In bivariate analysis, demographic and preoperative variables found to be significantly associated with 30-day mortality included age $80 years (P ¼ .033), transfer status (P < .0001), emergency case (P < .0001), ASA classification >3 (P < .0001), ventilator requirement within 48 hours of surgery (P < .0001), dialysis requirement (P ¼ .014), history of bleeding disorder (P ¼ .0078), acute pneumonia (P ¼ .022), transfusion >4 units of packed red blood cells in the 72 hours before surgery (P < .0001), systemic sepsis (P < .0001), white blood cell count >12 Â 10 9 / L (P < .0001), decreased hematocrit (P ¼ .0067), creatinine concentration $1.8 mg/dL (P ¼ .0046), and decreased albumin concentration (P ¼ .0003; Table I ). No intraoperative variables were significantly associated with 30-day mortality in bivariate analysis (Supplementary  Table II , online only). Patients with any postoperative complication (P < .0001), specifically pneumonia (P ¼ .017), unplanned intubation (P < .0001), ventilator requirement >48 hours (P < .0001), acute renal failure (P ¼ .0007), progressive renal insufficiency (P ¼ .016), cerebrovascular accident (P < .0001), cardiac arrest requiring cardiopulmonary resuscitation (P < .0001), septic shock (P < .0001), need for intraoperative or postoperative blood transfusions (P < .0001), or unplanned reoperation (P ¼ .0014), had a higher risk of 30-day mortality compared with those who did not have the respective complication (Table II) .
For the outcome of 30-day postoperative stroke, the following demographic and preoperative variables were noted to be significantly associated in bivariate analysis: transfer status (P ¼ .01), emergency case (P ¼ .008), transfusion >4 units in the 72 hours before surgery (P ¼ .03), open wound or wound infection before surgery (P ¼ .03), white blood cell count >12 Â 10 9 /L (P ¼ .02), and creatinine concentration $1.8 mg/dL (P ¼ .004; Supplementary Table III, online only). The only intraoperative variable found to be significantly associated with the outcome was left subclavian coverage (P ¼ .08).
For 30-day mortality, 14 preoperative variables met entry criteria for the multivariable model. Following backward logistic regression, the final model was composed of six independent predictors (Table III) /L (OR, 2.65; 95% CI, 1.41-4.96). The multivariable model performed well, with a C statistic of 0.81, and the Hosmer-Lemeshow goodness-of-fit test yielded a nonsignificant P of .41. Using cross-validation, the model was satisfactory in discrimination with a C statistic of 0.76.
In the final logistic regression model represented in Table III , the parameter estimates for all significant variables associated with 30-day mortality rounded most closely to 1. Thus, each risk factor was assigned an equal weight, and calculation of the risk score was simplified to the number of risk factors identified by the model present in a given patient, ranging from 0 to 4þ. Comparing predicted to observed probabilities for the outcome, increasing risk score was correlated with higher rates of 30-day mortality. When stratified by 0 (n ¼ 241), 1 (n ¼ 265), 2 (n ¼ 179), 3 (n ¼ 104), or 4þ (n ¼ 37) risk factors, the predicted probability of 30-day mortality was 1.33%, 3.40%, 8.41%, 19.34%, and 38.49%, respectively (Fig) .
DISCUSSION
As diagnostic and treatment strategies advance, the applications of TEVAR continue to change. Frequent re-examination of the risk factors employed in the clinical evaluation of patients is helpful in treatment decision analysis and for appropriate counseling of patients. This study examined preoperative risk factors for 30-day mortality after TEVAR in 826 patients using the ACS NSQIP database from 2013 to 2014 and developed a simple 6-point risk score. In this cohort, all-cause mortality was observed to be 7.6%. Compared with prior studies, minimal change has been seen in the rate of this outcome, which has ranged from 3% to 9.5% in the last decade. [15] [16] [17] We suspect that these outcomes are influenced by the increasing eligibility of the patient population, the new generations of stent grafts, and the modifications to operating room technique. [18] [19] [20] For instance, even within our study period, the U.S. Food and Drug Administration approved the use of the conformable Gore TAG (W. L. Gore & Associates, Flagstaff, Ariz) device for the new indication of isolated aortic lesion in 2013, soon followed by the Captivia Valiant (Medtronic, Santa Rosa, Calif) graft in early 2014. These regulatory changes are typically followed by an investigational device exemption trial targeting the latest diagnostic indication, and stringent inclusion and exclusion criteria may result in a selection bias toward patients with more favorable outcomes. The mortality rate of 7.6% noted in our study supports similar rates reported in certain industry-sponsored studies while contrasting from lower ones in other investigational device exemption trials. 2, 3, 6, 18, 21 Our finding, reported from a nationally sampled adjudicated data set, offers a more representative value of the outcome observed at centers performing the procedure across the country. Using a recent large real-world data set, we identified a number of preoperative variables that were risk factors for 30-day all-cause mortality and used them to create a clinical tool for stratification and counseling of patients under consideration for TEVAR. The lack of consistency in risk factors for mortality found across studies, even those completed with the same database, speaks to the dynamic environment in which TEVAR is being performed. It is likely that studies spanning similar or longer periods are drawing conclusions from different populations of patients.
Previous studies have identified variables associated with mortality using multivariable models. [15] [16] [17] 22, 23 Most recently, Kilic et al used the 2005 to 2012 ACS NSQIP database to generate a 30-point composite risk score composed of 10 risk factors, including age >70 years, body mass index <30 kg/m 2 , chronic obstructive pulmonary disease, functional status before surgery, preoperative blood urea nitrogen concentration >25 mg/dL, preoperative white blood cell count >12 Â 10 9 /L, emergency case, left subclavian artery coverage, thoracoabdominal extension, and mesenteric debranching. 24 Compared with that risk score, the one developed in our study does not require stratification of patients into low-, medium-, or high-risk tiers. Instead, predicted probability of the outcome may quickly be assessed solely on the basis of the number of risk factors present, as identified by the multivariable model. Although many risk factors, varying from older age to emergency case, have repeatedly been associated with 30-day mortality, 24,25 the model we constructed using this contemporary data set also yielded many different predictors. Of note, we did not find left subclavian artery coverage to be a significant risk factor for mortality, although it has previously been found to be predictive of both stroke and mortality. 24, 26 Similarly, chronic obstructive pulmonary disease was not significant in bivariate analysis, nor did it remain in the multivariable model, unlike prior findings. 15, 17, 24 Our results might suggest that these variables pertaining to more localized processes did not influence the outcome of mortality to the same extent in this sample population, whereas risk factors frequently representative of systemic alterations in health status, such as elevated white blood cell count or increased red blood cell transfusion requirement, were found to be significant. Although several of the identified risk factors may not be altered, others offer opportunities for preoperative optimization. For instance, patients found to have significantly elevated creatinine level may be medically optimized from a renal point of view, should timing of the procedure allow. Any intervention would then have to be investigated to assess its impact on outcomes.
Limitations of the study include those inherent in any retrospective data set analysis as well as specific constraints associated with the NSQIP database. First, many patient-and procedure-related variables, including comprehensive past surgical history and maximum aortic diameter, required to draw more informed conclusions about this population of patients are not captured in the data set. We acknowledge a potential for interprovider variation in procedure designations and coding patterns and an inability to verify patient-level information, given the deidentified nature of the database. Another consideration is that an adjunct procedure performed on any given patient during a separate hospital admission, either as a component of a staged procedure or for a separate indication, could be unaccounted for in the database, resulting in information bias. For these reasons, we chose not to evaluate the contribution of adjunct procedures toward or away from the outcomes of mortality or stroke. We recognize that other studies have incorporated procedures performed concurrently with TEVAR in their analyses to approximate their associations with outcomes of interest, and we need only bear in mind that these estimates could stray from the true value in either positive or negative direction. 23 Also, the NSQIP database does not include several postoperative complications often examined after endovascular procedures. Many of these missing variables, whether it be paraplegia or presence of endoleak, are recognized as chronic conditions or long-term outcomes and are challenging to identify accurately in the 30-day postoperative window. More extensive examination of these outcomes would be better suited for a study population with a longer follow-up period. Although the data are entered by trained clinical reviewers using consistent variable definitions, differences in interpretation are possible, and random errors in completion and accuracy may occur. The majority of variables included in the analysis were complete, and more specifically, none of the variables meeting selection for logistic regression modeling had missing values, demonstrating the rigor with which the database is maintained.
In addition, the model we developed had good discrimination in predicting mortality after TEVAR and continued to have acceptable discrimination with cross-validation.
In terms of clinical application of the model developed, the variables incorporated in the risk score may all be found easily with the quick review of a patient's medical record, so such a preoperative assessment would be quite feasible. Moving forward, coupled with clinical judgment, identification of these risk factors and consolidation of these identified variables into a simple prognostic tool may assist in the prospective, preoperative assessment of a patient's suitability for TEVAR. Alternatively, the patient and health care team would be aware before surgery if the patient were considered to be at increased risk for poor outcomes, prompting closer postoperative monitoring or planning for anticipatory interventions. We have taken initial steps toward prospective application of the risk score as well as external validation with our institutional series of TEVAR patients. Future research will pursue a multi-institutional data set containing more anatomic or procedure-focused variables to offer a better measure of its utility.
CONCLUSIONS
From the most recent sample of the ACS NSQIP database, we found that perioperative mortality and stroke rates have remained high after TEVAR. Of the variables identified as significant risk factors for 30-day all-cause mortality, many were representative of overall decline in health status or systemic disease, with higher ASA classification having the greatest magnitude of effect in the multivariable model. We incorporated these variables into a risk score that is simple and convenient and may serve as a prognostic tool in the preoperative risk stratification of patients being evaluated for TEVAR. Considering the contrast between predictors identified in our study and those found in other studies looking at mortality, we require additional evidence, ideally through prospective application of the risk score, to evaluate the reliability of our model and to substantiate its applicability to diverse patients with indications for TEVAR. 
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